Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of “Moderate Buy” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $52.00.

AGIO has been the subject of a number of research reports. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Scotiabank initiated coverage on Agios Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $51.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Caxton Associates LP raised its stake in Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after acquiring an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Agios Pharmaceuticals by 0.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 314 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after buying an additional 540 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at $37,000. Finally, Quest Partners LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at $40,000.

Agios Pharmaceuticals Stock Up 0.0 %

Agios Pharmaceuticals stock opened at $45.09 on Tuesday. The stock has a 50-day simple moving average of $44.64 and a 200 day simple moving average of $41.67. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $53.28. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -7.13 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. During the same period in the prior year, the firm earned ($1.51) earnings per share. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Agios Pharmaceuticals will post -4.87 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.